Christopher M. Cashman

Christopher M. Cashman is a seasoned executive with extensive experience in the pharmaceuticals and biotechnology industries. Currently serving as Chairman at MBF Therapeutics Inc. and a Director at Noble Biomaterials, EpiVario, Inc., and Telesis Therapeutics, Christopher M. Cashman has also held significant leadership roles, including Chairman and CEO at Marinus Pharmaceuticals, and Co-Founder and CEO at Protez Pharmaceuticals, which was acquired by Novartis. Additional roles include President of Protez Pharmaceuticals and President and CEO at Message Pharmaceuticals. Christopher M. Cashman holds a Master of Science in Economics from Purdue University and a Bachelor of Science in Business Administration and Management from the University of Minnesota.